ECTRIMS 2023

A clinical trial that was testing if treatments for multiple sclerosis (MS) could be discontinued in people with stable disease was terminated early after several patients who stopped treatment saw new disease activity.

A personalized dosing schedule for Tysabri (natalizumab) that aims to maintain blood levels of the drug above a certain threshold seems to be just as effective for controlling disease activity in relapsing-remitting…

People with relapsing-remitting multiple sclerosis (RRMS) who had an early start on high-efficacy disease-modifying therapies (DMTs) experience slower disability progression compared with those on escalation treatment, according to recent research. The study,…

Five of six people with secondary progressive multiple sclerosis (SPMS) treated with an experimental oral therapy called OCH saw no disease activity over six months in a small clinical trial. That’s compared with…

A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as the approved intravenous, or into-the-vein, formulation among people with multiple sclerosis (MS), according…

Infection with the Epstein-Barr virus (EBV) may prime the immune system to accidentally attack a brain protein called ANO2, new research shows. The findings may explain how EBV infection can lead to developing…

Six months of treatment with the experimental oral therapy vidofludimus calcium (IMU-838) led to significant reductions in a marker of nerve damage among people with relapsing-remitting multiple sclerosis (RRMS), according to a new…